Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1031 - Data-mining of 110 172 electronic patient records with the ConSoRe tool: An analysis of second primary cancer in a comprehensive cancer center

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Pierre Heudel

Citation

Annals of Oncology (2018) 29 (suppl_8): viii479-viii482. 10.1093/annonc/mdy294

Authors

P. Heudel1, T. Durand1, B. Fervers1, F. Gomez1, M. Rivoire1, T. Bachelot2, L. Claude1, C. Chassagne-Clement1, F. Pilleul1, T. Mognetti1, Y. Devaux1, J. Soubirou1, C. Lasset1, D. Perol1, G. Chvetzoff1, C. Pezet1, S. Beaupere1, P. Zrounba1, J.Y. Blay2

Author affiliations

  • 1 69, Centre Léon Bérard, 69008 - Lyon/FR
  • 2 Département D'oncologie Médicale, Centre Léon Bérard, 69008 - Lyon/FR
More

Resources

Abstract 1031

Background

We report a data-mining analysis of 110,172 electronic patient records (EPR) of the Leon Berard Comprehensive Cancer Center (CLB) over a 10 years period to identify characteristics of second primary cancers (SPC).

Methods

ConSoRe is a new generation data analytics solution using natural language processing to search aggregated data and perform advanced data mining. It was used for data extraction from EPR of 110,172 patients (pts), 47,257 men (M) and 62,915 women (W), treated at the CLB from 2007 to 2017. Patient characteristics, treatment and survival were extracted.

Results

Data extraction identified 88,622 pts with at least one cancer. Among them 7,430 (8.4%) had a SPC: 9% (3,475/38,554) in M and 7.9% (3955/50068) in W (p = 3 10-9). Of interest, only 4,296 SPC (57%) were already documented manually by the physicians in the dedicated forms. Mean age at diagnosis of first cancer (FC) is 55.1 years (y) in M and 51.8 y in W. Mean interval (MI) from diagnosis of FC to SPC is 5.3 years (4.4 in M, 6.1 in W; T test p = 4 10-23). Proportions of SPC among specific localization FC are: For M, head & neck cancer (n = 484/5,277, MI: 3.4 y), lymphoma (n = 336/5,611, MI: 5.1 y), prostate cancer (n = 334/4,643, MI: 6.1 y);for W, breast cancer (n = 1,502/21,447, MI: 8.6 y), soft tissue sarcoma (n = 321/3,683, MI: 4.5 y), lymphoma (n = 293/4,432, MI: 6.3 y). Time to SPC differ significantly depending on FC (Anova: p = 2 10-18).Pts with SPC were more likely to have received chemotherapy (31.1%) for their FC treatment compared to pts without SPC (20.8%; p = 1.6 10-94). Also, pts with SPC treated by chemotherapy for their FC had shorter MI than pts who did not (3.2 y versus 5.6 y). In multivariate analysis, time from diagnosis of FC to SPC is significantly linked to FC site and shorter when FC was treated with chemotherapy. SPC was significantly correlated to a worth survival: 19% of death with FC at the time of analysis, versus 27.6% of those with SPC (p = 9.7 10-57).

Conclusions

Screening over 100,000 EPR with ConSoRe enabled to retrieve SPC more exhaustively than the physician forms. ConSoRe will be validated in a broader series of 300,000 EPR and used to study SPC risk factors to enable prevention and early detection.

Clinical trial identification

Legal entity responsible for the study

Leon Berard Cancer Center.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.